The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib. (October 2022) - Pitman, J.; Dellamary, L.; Kc, S.; de los Rios, M.; Hood, J.